46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
PRX-PLUS has a unique product feature with its deep-impacting formula
This expanded partnership helps Evonik to streamline its distribution model in Asia Pacific
Subscribe To Our Newsletter & Stay Updated
